Cirrus Health

Cirrus Therapeutics is a clinical-stage biotechnology company focused on revolutionizing the treatment of age-related macular degeneration (AMD) and other chronic blinding diseases through ocular immunology. The company's lead program is a novel adeno-associated virus (AAV) gene therapy designed to restore levels of IRAK-M, a key immune regulator that declines with age and is significantly reduced in patients with dry AMD. By targeting the underlying immune dysregulation, Cirrus aims to provide a one-time treatment that can halt disease progression and preserve vision. Additionally, the company is developing a next-generation retinal pigment epithelium (RPE) cell therapy for advanced geographic atrophy. Headquartered in Cambridge, Massachusetts, with significant operations in Singapore, Cirrus is leveraging breakthrough research from the University of Bristol and UCL to extend ocular healthspan.